Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 188.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 398 shares of the company’s stock after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC’s holdings in Vaxcyte were worth $33,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PCVX. Amalgamated Bank increased its position in Vaxcyte by 8.6% during the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after purchasing an additional 322 shares during the period. Principal Financial Group Inc. increased its position in Vaxcyte by 186.2% during the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock worth $6,022,000 after purchasing an additional 34,287 shares during the period. Atria Investments Inc acquired a new position in Vaxcyte during the 3rd quarter worth approximately $286,000. Los Angeles Capital Management LLC acquired a new position in Vaxcyte during the 3rd quarter worth approximately $1,016,000. Finally, Chartwell Investment Partners LLC increased its position in Vaxcyte by 24.1% during the 3rd quarter. Chartwell Investment Partners LLC now owns 14,146 shares of the company’s stock worth $1,617,000 after purchasing an additional 2,745 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,250 shares of company stock valued at $4,550,258. 3.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PCVX has been the topic of several recent analyst reports. Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Stock Performance

PCVX stock opened at $73.24 on Thursday. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock’s 50 day moving average price is $82.65 and its 200 day moving average price is $94.44. The firm has a market cap of $9.43 billion, a P/E ratio of -15.92 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.